Trending NewsTrending NewsNASDAQ:XENE Xenon Pharmaceuticals (XENE) Stock Price, News & Analysis $38.02 0.00 (0.00%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$38.05 +0.03 (+0.08%) As of 10/2/2026 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Xenon Pharmaceuticals Stock (NASDAQ:XENE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Xenon Pharmaceuticals alerts:Sign Up Key Stats Today's Range$37.26▼$39.1050-Day Range$36.56▼$65.7852-Week Range$36.07▼$72.66Volume1.94 million shsAverage Volume2.62 million shsMarket Capitalization$3.68 billionP/E RatioN/ADividend YieldN/APrice Target$70.27Consensus RatingModerate Buy Company Overview Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses research in ion channels and neuronal signaling to identify potential treatments for conditions with significant unmet medical needs. Xenon’s lead investigational medicine is azetukalner, also known as XEN1101, a selective potassium channel opener being evaluated for epilepsy and major depressive disorder. The company is also advancing additional programs aimed at genetically defined epilepsies and other disorders of the central nervous system. Its medicines remain in development and are subject to clinical and regulatory review. Founded in 1996 and headquartered in Vancouver, British Columbia, Xenon conducts research and clinical development activities in North America and works with external collaborators to advance its programs. The company’s operations are supported by a leadership team with experience in biotechnology, pharmaceutical development and neuroscience, including President and Chief Executive Officer Ian Mortimer.AI Generated. May Contain Errors. Read More Xenon Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreXENE MarketRank™: Xenon Pharmaceuticals scored higher than 76% of companies evaluated by MarketBeat, and ranked 136th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingXenon Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 2 strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialXenon Pharmaceuticals has a consensus price target of $70.27, representing about 84.8% upside from its current price of $38.02.Amount of Analyst CoverageXenon Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Xenon Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($4.70) to ($4.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenon Pharmaceuticals is -8.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenon Pharmaceuticals is -8.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenon Pharmaceuticals has a P/B Ratio of 5.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Xenon Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.87% of the float of Xenon Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverXenon Pharmaceuticals has a short interest ratio ("days to cover") of 12.22, which indicates bearish sentiment.Change versus previous monthShort interest in Xenon Pharmaceuticals has recently increased by 1.59%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXenon Pharmaceuticals does not currently pay a dividend.Dividend GrowthXenon Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.90 News SentimentXenon Pharmaceuticals has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Xenon Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest5 people have searched for XENE on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Xenon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership4.4 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Xenon Pharmaceuticals in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $614,753.00 in company stock, which represents 0.0167% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Xenon Pharmaceuticals insiders have bought 57.64% more of their company's stock than they have sold. Specifically, they have bought $1,681,200.00 in company stock and sold $1,066,447.00 in company stock.Percentage Held by Insiders2.91% of the stock of Xenon Pharmaceuticals is held by insiders.Percentage Held by Institutions95.45% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xenon Pharmaceuticals' insider trading history. Receive XENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XENE Stock News HeadlinesXenon CFO buys 15,000 sharesOctober 4 at 4:02 AM | americanbankingnews.comXenon Pharmaceuticals (NASDAQ:XENE) Stock: Insider Ian Mortimer Purchases 30,000 SharesOctober 3 at 4:22 AM | americanbankingnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it. | Banyan Hill Publishing (Ad)Xenon Pharmaceuticals (NASDAQ:XENE) Stock: Insider Thomas Patrick Kelly Buys 15,000 SharesOctober 3 at 4:22 AM | americanbankingnews.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Rating of "Moderate Buy" from BrokeragesOctober 3 at 3:03 AM | americanbankingnews.comXenon Pharmaceuticals (NASDAQ:XENE) Shares Climb 5.2% After Insider Buying ActivityOctober 3 at 2:24 AM | americanbankingnews.comWall Street Zen Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to "Sell"October 3 at 1:48 AM | americanbankingnews.comInsider Buying: Xenon Pharmaceuticals (NASDAQ:XENE) CFO Buys $559,800.00 in StockOctober 2 at 5:07 AM | insidertrades.comSee More Headlines XENE Stock Analysis - Frequently Asked Questions How have XENE shares performed this year? Xenon Pharmaceuticals' stock was trading at $44.82 at the beginning of the year. Since then, XENE shares have decreased by 15.2% and is now trading at $38.02. How were Xenon Pharmaceuticals' earnings last quarter? Xenon Pharmaceuticals Inc. (NASDAQ:XENE) released its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.16) by $0.05. Read the conference call transcript. When did Xenon Pharmaceuticals IPO? Xenon Pharmaceuticals (XENE) raised $44 million in an IPO on Friday, October 17th 2014. The company issued 4,000,000 shares at a price of $10.00-$12.00 per share. How do I buy shares of Xenon Pharmaceuticals? Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xenon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xenon Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Deckers Outdoor (DECK), Adobe (ADBE) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings8/06/2026Today10/04/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, XENE's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:XENE CIK1582313 Webwww.xenon-pharma.com Phone(604) 484-3300Fax604-484-3450Employees364Year Founded1996Price Target and Rating Average Price Target for Xenon Pharmaceuticals$70.27 High Price Target$97.00 Low Price Target$46.00 Potential Upside/Downside+84.8%Consensus RatingModerate Buy Rating Score (0-4)2.94 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($4.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$345.91 million Net MarginsN/A Pretax MarginN/A Return on Equity-43.98% Return on Assets-41.72% Debt Debt-to-Equity RatioN/A Current Ratio21.01 Quick Ratio21.02 Sales & Book Value Annual Sales$7.50 million Price / Sales490.05 Cash FlowN/A Price / Cash FlowN/A Book Value$7.53 per share Price / Book5.05Miscellaneous Outstanding Shares96,670,000Free Float93,853,000Market Cap$3.68 billion OptionableOptionable Beta0.60 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:XENE) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
